beat · 14 stories
A 59-person qualitative study finds health workers and community members in sub-Saharan Africa see potential for AI in maternal, sexual, and reproductive health, but most lack the awareness to deploy it safely.
The Michael J. Fox Foundation's flagship Parkinson's cohort, the Parkinson's Precision Medicine Initiative (PPMI), just gained a proteomic layer, giving global researchers a shared substrate for subtype and progression work, not a treatment.
$7 billion health-AI vendor told referral-program partners payments end in 30 days, six days before STAT's investigation into the same practice.
Lilly filed six new federal suits the same day it asked platforms, payment processors, and federal regulators to sever the supply chain for retatrutide, a Phase 3 obesity drug that isn't approved in any country.
A new analysis of 25,213 U.S. adults without diabetes on GLP-1 drugs, the class behind Ozempic, Wegovy, Mounjaro, and Zepbound, finds a slow regain begins after the one-year mark.
The 'brain-inspired hardware' label hides a clean split: chips that imitate neurons, and lab-grown neural tissue used as a processor.
Eight large pharmaceutical companies have paid for early access to Vivodyne's twelve robotic labs and a tissue chip the size of a semiconductor wafer that hosts hundreds of living human tissues. Independent benchmarks are still pending.
Three decades of declining returns made each new drug costlier, and the post-COVID crash is the first pressure strong enough to break that pattern, if the surviving hubs build a different model.
HHS, the Office of National Drug Control Policy (ONDCP), and HUD formally replace a decade of federal homelessness policy with a treatment-first model that conditions housing access on recovery engagement.
WHO Director-General Tedros Adhanom Ghebreyesus said President Trump's new childhood vaccine order contradicts the best available science, and a country-by-country data check shows the U.S. would move away from Europe.
A 50-patient study mapped a 20–35 Hz rhythm between a deep brain structure and frontal cortex that explains who benefits from the implant therapy.
The method pairs a neural network with classical image processing to track cell survival in 3D-bioprinted scaffolds, the layer-by-layer-printed living tissue used in lab research.